(firstQuint)Phase 3 Study of Yimitasvir Phosphate Capsules.

 A phase III, multicenter, single-arm, open-label study to assess the safety, tolerability and antiviral activity of DAG181/SOF combination for 12 weeks in adult subjects with chronic genotype 1 HCV infection.

 Approximately 360 HCV genotype 1 subjects without cirrhosis will be enrolled, treatment-experienced subjects are 20%.

 All subjects will receive DAG181 100 mg/ SOF 400 mg once daily for 12 weeks,with subsequent observation for 24 weeks after cessation of treatment.

.

 Phase 3 Study of Yimitasvir Phosphate Capsules@highlight

The safety, tolerability and antiviral activity of DAG181/SOF in treatment-naive and treatment-experienced patients with chronic hepatitis C virus (HCV) genotype 1 infection.

